Dyne Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone to the 41st Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and [Adarsh Ahyan] from the team.
Our next presenting company is Dyne, and speaking on behalf of the company, we have CEO, Joshua Brumm. Before I turn it over to Josh, I just wanted to highlight that for Q&A, After the formal presentation, there is an Ask-a-Question button in the portal. I'm happy to ask a question on your behalf, and we'll also be taking live questions from the audience.
So with that, Josh, over to you.
Great. Thanks, Tess, and thanks to JPMorgan for inviting us here today to speak on behalf of Dyne. So, pleasure to see many of you today in the audience, and always look forward to sharing the exciting opportunity we have in front of us here at Dyne Therapeutics.
Before I begin, I'd just like to mention forward-looking statements. We'll be making some today. If
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
